DermTech Intends To Continue Laboratory Operations During Strategic Review
DermTech Intends To Continue Laboratory Operations During Strategic Review
DermTech 打算在戰略審查期間繼續實驗室運營
The Company anticipates incurring a one-time restructuring charge of approximately $1.6 million in the second quarter of 2024 in connection with these restructuring actions. The company believes it has sufficient capacity to process orders for the DermTech Melanoma Test (DMT).
該公司預計，2024年第二季度將產生與這些重組行動有關的一次性重組費用約160萬美元。該公司認爲，它有足夠的能力處理DermTech黑色素瘤測試（DMT）的訂單。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。